MTX Stock Analysis: Minerals Technologies | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 2.058m USD | 12M Return: 8.4% | US6031581068 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.0M
EPS Trend: 50.4%
Qual. Beats: 0
Rev. Trend: -53.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Minerals Technologies Inc. (MTX) is a specialty chemicals and mineral-based products company operating two main segments: Consumer & Specialties and Engineered Solutions. The Consumer & Specialties segment supplies household and personal care products (including SIVO cat litter), as well as precipitated calcium carbonate (PCC) and ground calcium carbonate (GCC) additives used primarily in the paper, paperboard, and fiber-based packaging industries. The Engineered Solutions segment provides high-temperature refractory products for industrial casting, environmental and infrastructure solutions (such as geosynthetic clay liners and vapor intrusion systems), carbon composites under the PYROID brand, and filtration and well testing services.
The company sells primarily through a direct sales force supplemented by regional distributors, serving customers across the United States, Canada, Latin America, Europe, Africa, and Asia. As a mid-cap stock in the GICS Specialty Chemicals sub-industry, MTX follows a B2B business model, supplying engineered mineral inputs to diverse industrial end markets including automotive, construction, packaging, agriculture, and water treatment, which diversifies revenue across multiple economic cycles.
- Paperboard packaging demand drives PCC specialty additives volume
- Auto and heavy truck foundry output lifts refractory sales
- SIVO cat litter brand expands share in pet care market
| Net Income: -67.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.87 > 1.0 |
| NWC/Revenue: 16.54% < 20% (prev 27.62%; Δ -11.08% < -1%) |
| CFO/TA 0.07 > 3% & CFO 230.3m > Net Income -67.3m |
| Net Debt (618.7m) to EBITDA (76.8m): 8.06 < 3 |
| Current Ratio: 1.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.1m) vs 12m ago -1.58% < -2% |
| Gross Margin: 24.46% > 18% (prev 25.41%; Δ -0.95% > 0.5%) |
| Asset Turnover: 61.79% > 50% (prev 59.73%; Δ 2.06% > 0%) |
| Interest Coverage Ratio: -0.39 > 6 (EBIT TTM -21.2m / Interest Expense TTM 54.9m) |
| A: 0.10 (Total Current Assets 1.18b - Total Current Liabilities 828.5m) / Total Assets 3.50b |
| B: 0.67 (Retained Earnings 2.33b / Total Assets 3.50b) |
| C: -0.01 (EBIT TTM -21.2m / Avg Total Assets 3.48b) |
| D: 0.81 (Book Value of Equity 1.54b / Total Liabilities 1.92b) |
| Altman-Z'' = 3.64 = AA |
| DSRI: 0.93 (Receivables 412.6m/425.9m, Revenue 2.15b/2.06b) |
| GMI: 1.04 (GM 25.41% / 24.46%) |
| AQI: 0.99 (AQ_t 0.37 / AQ_t-1 0.37) |
| SGI: 1.04 (Revenue 2.15b / 2.06b) |
| TATA: -0.09 (NI -67.3m - CFO 230.3m) / TA 3.50b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of October 07, 2026, the stock is trading at USD 65.98 with a total of 168,775 shares traded. Over the past week, the price has changed by -0.20%, over one month by -6.44%, over three months by -11.11% and over the past year by +8.38%.
Current recommended Stop Loss: 63.20 (which is 4.2% or 1.7 ATR below the current price).
Minerals Technologies has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy MTX.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 92.5 | 40.2% |
P/E Forward = 9.3809
P/S = 0.9584
P/B = 1.3476
P/EG = 2.2199
Revenue TTM = 2.15b USD
EBIT TTM = -21.2m USD
EBITDA TTM = 76.8m USD
Long Term Debt = 952.9m USD (from longTermDebt, last quarter)
Short Term Debt = 12.0m USD (from shortTermDebt, last quarter)
Debt = 964.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 618.7m USD (calculated: Debt 964.9m - CCE 346.2m)
Enterprise Value = 2.68b USD (2.06b + Debt 964.9m - CCE 346.2m)
Interest Coverage Ratio = -0.39 (Ebit TTM -21.2m / Interest Expense TTM 54.9m)
EV/FCF = 22.25x (Enterprise Value 2.68b / FCF TTM 120.3m)
FCF Yield = 4.49% (FCF TTM 120.3m / Enterprise Value 2.68b)
FCF Margin = 5.60% (FCF TTM 120.3m / Revenue TTM 2.15b)
Net Margin = -3.13% (Net Income TTM -67.3m / Revenue TTM 2.15b)
Gross Margin = 24.46% ((Revenue TTM 2.15b - Cost of Revenue TTM 1.62b) / Revenue TTM)
Gross Margin QoQ = 24.18% (prev 23.97%)
Tobins Q-Ratio = 0.77 (Enterprise Value 2.68b / Total Assets 3.50b)
Interest Expense / Debt = 5.69% (Interest Expense 54.9m / Debt 964.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -16.7m (EBIT -21.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.43 (Total Current Assets 1.18b / Total Current Liabilities 828.5m)
Debt / Equity = 0.62 (Debt 964.9m / totalStockholderEquity, last quarter 1.54b)
Debt / EBITDA = 8.06 (Net Debt 618.7m / EBITDA 76.8m)
Debt / FCF = 5.14 (Net Debt 618.7m / FCF TTM 120.3m)
Total Stockholder Equity = 1.67b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.94% (Net Income -67.3m / Total Assets 3.50b)
RoE = -4.04% (Net Income TTM -67.3m / Total Stockholder Equity 1.67b)
RoCE = -0.81% (EBIT -21.2m / Capital Employed (Equity 1.67b + L.T.Debt 952.9m))
RoIC = -0.65% (negative operating profit) (NOPAT -16.7m / Invested Capital 2.57b)
WACC = 7.03% (E(2.06b)/V(3.02b) * Re(8.22%) + D(964.9m)/V(3.02b) * Rd(5.69%) * (1-Tc(0.21)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.23 | Cagr: -1.80%
[DCF] Terminal Value 77.97% ; FCFF base≈107.7m ; Y1≈123.4m ; Y5≈181.6m
[DCF] Fair Price = 67.93 (EV 2.73b - Net Debt 618.7m = Equity 2.11b / Shares 31.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 50.39 | EPS CAGR: 4.28% | SUE: -0.57 | # QB: 0
Revenue Correlation: -53.80 | Revenue CAGR: -1.09% | SUE: -0.73 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.53 | Chg30d=-1.81% | Revisions=-50% | Analysts=4
EPS current Year (2026-12-31): EPS=5.98 | Chg30d=-0.77% | Revisions=-17% | GrowthEPS=+8.3% | GrowthRev=+5.5%
EPS next Year (2027-12-31): EPS=7.00 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=+17.1% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: -58% (up=1, down=8)